Aspire-Lakewood (ASBP) vs CalciMedica (CALC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aspire-Lakewood (ASBP) has outperformed CalciMedica (CALC) over the past year, gaining 83.8% versus a loss of 92.3%. Aspire-Lakewood is the larger company by market cap ($10.0 million vs $8.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASBP | CALC |
|---|---|---|
| Share price | $7.13 | $1.26 |
| Market cap | $10.00M | $8.69M |
| 1-day change | -5.44% | +7.69% |
| YTD return | +35.04% | -96.18% |
| 1-year return | +83.76% | -92.34% |
| EPS (TTM) | $-30.89 | $-4.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.20K | — |
| Net income (latest FY) | $-24.48M | $-29.56M |
| Gross margin | -1.87% | — |
| Operating margin | -312016.95% | — |
| Net margin | -394725.06% | — |
| 52-week high | $9.50 | $36.00 |
| 52-week low | $0.11 | $1.00 |
| Distance from 52-week high | -24.95% | -96.50% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +3868.25% |
| Average volume | 29.24K | 80.15K |
| Shares outstanding | 1.40M | 6.90M |
| Employees | — | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASBP has outperformed CALC by 176.1 percentage points over the past year.
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Health Care · Biotechnology: Pharmaceutical Preparations
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
ASBP vs CALC FAQ
Which is bigger, Aspire-Lakewood or CalciMedica?
Aspire-Lakewood (ASBP) is larger, with a market capitalization of $10.00M compared with $8.69M for CalciMedica (CALC).
Which stock has performed better over the past year, ASBP or CALC?
ASBP returned +83.76% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.
Are Aspire-Lakewood and CalciMedica in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.